Subgroup analysis of CDR‐SB mean change at week 12 for all treatment arms was comparable to placebo, except for nominal differences in the 5‐mg arm versus placebo for the following subgroups: participants who were not on symptomatic treatment for AD, female, age ≤ 65, between age 65 and <75, White, or APS2 negative (APS2−) (Table S2). Here, NUDT10 is linked to Alzheimer disease.